September 7, 2026

GSK plc (GSK) Stock Analysis: Exploring a 17.41% Potential Upside in the Dynamic Healthcare Sector

As one of the stalwarts in the healthcare sector, GSK plc (NYSE: GSK) presents an intriguing opportunity for investors looking to capitalize on the pharmaceutical industry...

Cencora, Inc. (COR) Stock Analysis: Robust Growth in Medical Distribution with an 11.59% Upside Potential

Cencora, Inc. (NYSE: COR), formerly known as AmerisourceBergen Corporation, stands as a formidable player in the healthcare sector, specifically within the medical distribution industry. With a..

Teva Pharmaceutical Industries (TEVA) Stock Analysis: A 14% Upside Potential Amidst Analyst Optimism

Teva Pharmaceutical Industries (NYSE: TEVA), a key player in the healthcare sector, continues to draw significant investor interest with its robust presence in the specialty and..

Labcorp Holdings Inc. (LH) Stock Analysis: Exploring the 4.47% Potential Upside in the Healthcare Diagnostics Leader

Labcorp Holdings Inc. (NYSE: LH), a dominant force in the healthcare diagnostics and research sector, stands at a pivotal point with its current stock price at..

HCA Healthcare, Inc. (HCA) Stock Analysis: Balancing Growth and Stability with an 11.48% Upside

Investors eyeing the healthcare sector should take note of HCA Healthcare, Inc. (NYSE: HCA), a major player in the medical care facilities industry with a market..

Novartis AG (NVS): Investor Outlook on Healthcare Giant with Robust Free Cash Flow and High ROE

Novartis AG (NYSE: NVS), a Swiss-based healthcare titan, is a key player in the drug manufacturing industry, focusing on a diverse range of therapeutic areas including..

McKesson Corporation (MCK) Stock Analysis: Valuation Insights and Growth Potential in Healthcare Distribution

McKesson Corporation (NYSE: MCK), a titan in the healthcare distribution sector, continues to exhibit remarkable resilience and growth potential despite a complex market landscape. With a..

Veeva Systems Inc. (VEEV) Stock Analysis: Strong Buy Ratings Amid Robust Revenue Growth

Veeva Systems Inc. (NYSE: VEEV), a leader in cloud-based solutions tailored for the life sciences industry, presents a compelling investment opportunity. With a market capitalization of..

Thermo Fisher Scientific Inc. (TMO) Stock Analysis: A Leading Healthcare Giant with Strong Revenue Growth Prospects

Thermo Fisher Scientific Inc. (NYSE: TMO), a powerhouse in the healthcare sector, continues to capture the attention of investors with its robust market presence and influential..

Eli Lilly and Company (LLY) Stock Analysis: Exploring a Potential 14.46% Upside in the Healthcare Giant

Eli Lilly and Company (NYSE: LLY) stands as a towering figure in the healthcare sector with a market capitalization of $1.02 trillion. This Indianapolis-based pharmaceutical giant,..

Becton, Dickinson and Company (BDX) Stock Analysis: Exploring a 5.91% Potential Upside in the Healthcare Giant

Becton, Dickinson and Company (NYSE: BDX), a stalwart in the healthcare sector, is capturing investor attention with its substantial market cap of $50.32 billion and a..

Medtronic plc (MDT) Stock Analysis: Unpacking a Potential 11.25% Upside in the Medical Device Sector

Medtronic plc (NYSE: MDT), a global leader in medical devices, offers a compelling investment opportunity for investors seeking exposure in the healthcare sector. With a market..

Vertex Pharmaceuticals (VRTX) Stock Analysis: A Biotech Titan with 4.29% Upside and Robust Buy Ratings

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) stands as a formidable player in the biotechnology sector, showcasing a market capitalization of $138.42 billion. Known for its innovative approach..

Haleon plc (HLN) Stock Analysis: Exploring a 24.94% Potential Upside in Healthcare Investment

Haleon plc (HLN), a prominent player in the healthcare sector, is capturing the attention of investors with its strong market presence and promising growth trajectory. With..

Danaher Corporation (DHR) Investor Outlook: A Strong ‘Buy’ with a 10% Upside Potential

Danaher Corporation, trading under the ticker DHR on the New York Stock Exchange, stands as a titan in the healthcare sector, specifically within the diagnostics and..

Boston Scientific Corporation (BSX) Stock Analysis: Exploring the 31% Potential Upside

Boston Scientific Corporation (NYSE: BSX) stands as a titan in the healthcare sector, specifically within the medical devices industry. With a market capitalization of $69.27 billion,..

Ampeak Energy advances Uskmouth battery portfolio with £7.8m AW1 investment

Ampeak Energy has secured £7.8 million for its AW1 battery project as construction progresses and its larger AW2 development moves forward with planning approval...

AstraZeneca’s Etcamah approved in US for ESR1-mutated advanced breast cancer

The FDA has approved Etcamah (camizestrant) with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer after detection of an emerging ESR1 mutation, based on Phase..

Grainger reports strong rental demand and outlines FY29 growth plan

Grainger said occupancy remained high at 96% and like-for-like rental growth reached 3% as it reaffirmed plans to grow earnings by 35% from FY25 to FY29,..

Standard Life H1 operating profit rises 25% as 2026 targets remain on track

Standard Life reported £563m of adjusted operating profit and £745m of operating cash generation in H1 2026, with all full-year targets on track...
Search

Funds

September 7, 2026

Ampeak Energy advances Uskmouth battery portfolio with £7.8m AW1 investment

Ampeak Energy has secured £7.8 million for its AW1 battery project as construction progresses and its larger AW2 development moves forward with planning approval...

AstraZeneca’s Etcamah approved in US for ESR1-mutated advanced breast cancer

The FDA has approved Etcamah (camizestrant) with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer after detection of an emerging ESR1 mutation, based on Phase III SERENA-6 results showing a 56% reduction in the risk of disease progression or death...

Grainger reports strong rental demand and outlines FY29 growth plan

Grainger said occupancy remained high at 96% and like-for-like rental growth reached 3% as it reaffirmed plans to grow earnings by 35% from FY25 to FY29, reduce net debt and accelerate non-core asset disposals...

Standard Life H1 operating profit rises 25% as 2026 targets remain on track

Standard Life reported £563m of adjusted operating profit and £745m of operating cash generation in H1 2026, with all full-year targets on track...
Search

Funds

September 7, 2026

FTSE 100

Funds